NCT Number: NCT00538811
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with interferon-alpha. Enhancement of immune responses, especially those related to type-1 T helper cell activity, may contribute to better efficacy in combining ribavirin with IFN-alpha for treatment of chronic hepatitis C. The aim of the present study is to evaluate the efficacy and safety of a triple regimen, a combination treatment with Interferon gamma, Interferon alfa-2b plus Ribavirin in patients who have not previously responded to interferon alpha in combination of ribavirin.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2 / Phase 3
Primary location
Medicare Clinic, Karachi, Pakistan
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Non-responders and relapsers to previous interferon and ribavirin therapy given for six months
- HCV genotype 3
- Compensated liver disease
- Hb ≥10 g/dl (females),≥11 g/dl (males)
- Platelets count ≥ 100,000 / cubic mm
- Neutrophils count ≥1,500/cubic mm
- ≥18 years to ≤ 70 years.
- At least one abnormal ALT value in the last year.
- TSH level within normal limits.
- Non pregnant adult females.
- Absence of drug or alcohol abuse.
- Informed consent given by the patient
Exclusion criteria
- Patient younger than 18 yrs and older than 70 yrs.
- Hepatitis B or HIV co-infection.
- Severe renal dysfunction or creatinine clearance less than 50 ml/min
- Pregnant women or breast feeding women.
- Suspected hypersensitivity to Interferon alpha, gamma or ribavirin.
- Decompensated liver cirrhosis.
- History or any other evidence of other causes of CLD other than hepatitis C infection ( like hemochromatosis,, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure, Wilson's disease,Drug induced liver disease)
- Active malignant disease.
- Any known pre-existing medical condition that could interfere with subject's participation or completion of study such as psychiatric condition, seizures disorder requiring medications, co existing heart diseases, lung diseases, poorly controlled diabetes, auto immune diseases, gout)
- History of interferon and/or ribavirin intolerance
Treatment and study plan
interferon alpha-2b, ribavirin, amantadine
DrugSponsors and collaborators
Lead sponsor
Aga Khan University
Other
Registry information
Official study title
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin
Important dates
- First posted
- Oct 3, 2007
- Registry last updated
- Oct 27, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Reaching mEthadone Users Attending Community pHarmacies With HCV
NCT03935906
Blood-Borne Infections, Communicable Diseases
Melbourne, Australia
View Trial DetailsEpidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
NCT00004850
Blood-Borne Infections, Communicable Diseases
Bethesda, Maryland, United States
View Trial DetailsTele-Harm Reduction
NCT05208697
Blood-Borne Infections, Communicable Diseases
Fort Lauderdale, Florida, United States
View Trial DetailsExpanding the Pool in Orthotopic Heart Transplantation
NCT03222531
Blood-Borne Infections, Cardiac Transplant
Pittsburgh, Pennsylvania, United States
View Trial Details